Overview

• Lyra reports Q3 2025 net loss of $6.0 mln, down from $11.9 mln last year

• Company plans new Phase 3 trial for LYR-210, aiming for NDA submission

• Cash reserves expected to fund operations into Q3 2026

Outlook

• Lyra plans new Phase 3 trial for LYR-210, targeting NDA submission

• Company anticipates cash reserves to fund operations until Q3 2026

Result Drivers

• R&D EXPENSES - Decrease in R&D expenses due to completion of ENLIGHTEN 2 trial and workforce reduction

• G&A EXPENSES - Reduction in general and administrative expenses due to lower employee costs and operational savings

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Lyra Therapeutics Inc is $23.00, about 81.6% above its November 11 closing price of $4.24

Press Release: ID:nGNX13nXTP

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)